Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 5 (2008), Issue 10 (October)

  1. Pathways to diagnosis for Black men and White men found to have prostate cancer: the PROCESS cohort study.
    Br J Cancer, 99(7): 1040-5. [Abstract] [Full-text]
  2. Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion.
    Br J Cancer, 99(7): 1114-20. [Abstract] [Full-text]
  3. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells.
    J Cell Physiol, 217(3): 569-76. [Abstract] [Full-text]
  4. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo.
    Carcinogenesis, 29(10): 2001-10. [Abstract] [Full-text]
  5. Novel amiodarone-doxorubicin cocktail liposomes enhance doxorubicin retention and cytotoxicity in DU145 human prostate carcinoma cells.
    J Med Chem, 51(19): 6067-74. [Abstract] [Full-text]
  6. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells.
    J Biol Chem, 283(41): 27707-16. [Abstract] [Full-text]
  7. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.
    Int J Cancer, 123(11): 2636-43. [Abstract] [Full-text]
  8. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
    Int J Cancer, 123(11): 2574-9. [Abstract] [Full-text]
  9. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk.
    Int J Cancer, 123(11): 2644-50. [Abstract] [Full-text]
  10. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38.
    Int J Cancer, 123(11): 2532-42. [Abstract] [Full-text]
  11. Validation of quality indicators for radical prostatectomy.
    Int J Cancer, 123(11): 2651-7. [Abstract] [Full-text]
  12. Definitive radiotherapy for prostate cancer.
    Am J Clin Oncol, 31(5): 496-503. [Abstract] [Full-text]
  13. Metastatic prostatic carcinoma presenting as fulminant hepatic failure.
    South Med J, 101(10): 1049-50. [Abstract] [Full-text]
  14. Perceived family history risk and symptomatic diagnosis of prostate cancer: the North Carolina Prostate Cancer Outcomes study.
    Cancer, 113(8): 2180-7. [Abstract] [Full-text]
  15. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features.
    Cancer, 113(8): 2068-72. [Abstract] [Full-text]
  16. Predictors of patient preferences and treatment choices for localized prostate cancer.
    Cancer, 113(8): 2058-67. [Abstract] [Full-text]
  17. Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy.
    Pathol Int, 58(11): 687-94. [Abstract] [Full-text]
  18. Antidiabetic medication and prostate cancer risk: a population-based case-control study.
    Am J Epidemiol, 168(8): 925-31. [Abstract] [Full-text]
  19. An N-terminal 78 amino acid truncation of REIC/Dkk-3 effectively induces apoptosis.
    Biochem Biophys Res Commun, 375(4): 614-8. [Abstract] [Full-text]
  20. TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells.
    BMC Cancer, 8: 282. [Abstract] [Full-text]
  21. Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care.
    Arch Intern Med, 168(18): 2033-40. [Abstract] [Full-text]
  22. Is PTEN loss associated with clinical outcome measures in human prostate cancer?
    Br J Cancer, 99(8): 1296-301. [Abstract] [Full-text]
  23. Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer.
    Mol Cancer Res, 6(10): 1639-48. [Abstract] [Full-text]
  24. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.
    Mol Cancer Res, 6(10): 1594-606. [Abstract] [Full-text]
  25. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.
    Cancer Res, 68(20): 8607-15. [Abstract] [Full-text]
  26. A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: involvement of nuclear factor-kappaB signaling.
    Cancer Res, 68(20): 8564-72. [Abstract] [Full-text]
  27. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice.
    Cancer Res, 68(20): 8555-63. [Abstract] [Full-text]
  28. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.
    Cancer Res, 68(20): 8516-24. [Abstract] [Full-text]
  29. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    J Clin Oncol, 26(30): 4928-33. [Abstract] [Full-text]
  30. The significance of monoamine oxidase-A expression in high grade prostate cancer.
    J Urol, 180(5): 2206-11. [Abstract] [Full-text]
  31. Mass screening for prostate cancer in Korea: a population based study.
    J Urol, 180(5): 1949-52; discussion 1952-3. [Abstract] [Full-text]
  32. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    J Urol, 180(5): 1975-8; discussion 1978-9. [Abstract] [Full-text]
  33. Physician clinical experience and inappropriate prostate specific antigen screening: evidence from an Asian country.
    J Urol, 180(5): 1954-8; discussion 1958. [Abstract] [Full-text]
  34. Prostate specific antigen assay standardization bias could affect clinical decision making.
    J Urol, 180(5): 1959-62; discussion 1962-3. [Abstract] [Full-text]
  35. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    J Urol, 180(5): 1980-4; discussion 1985. [Abstract] [Full-text]
  36. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    J Urol, 180(5): 2005-9; discussion 2009-10. [Abstract] [Full-text]
  37. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
    J Urol, 180(5): 1964-7; discussion 1967-8. [Abstract] [Full-text]
  38. Patterns of care for radical prostatectomy in the United States from 2003 to 2005.
    J Urol, 180(5): 1969-74. [Abstract] [Full-text]
  39. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    J Urol, 180(5): 2011-7; discussion 2017-8. [Abstract] [Full-text]
  40. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
    J Urol, 180(5): 1986-92. [Abstract] [Full-text]
  41. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
    J Urol, 180(5): 1938-41; discussion 1941. [Abstract] [Full-text]
  42. Immunocytological and preliminary immunohistochemical studies of prothymosin alpha, a human cancer-associated polypeptide, with a well-characterized polyclonal antibody.
    J Histochem Cytochem, 56(11): 1023-31. [Abstract] [Full-text]
  43. The autocrine human secreted PDZ domain-containing protein 2 (sPDZD2) induces senescence or quiescence of prostate, breast and liver cancer cells via transcriptional activation of p53.
    Cancer Lett, 271(1): 64-80. [Abstract] [Full-text]
  44. Molecular alterations in prostate cancer.
    Cancer Lett, 271(1): 13-24. [Abstract] [Full-text]
  45. Verification of dose delivery for a prostate sIMRT treatment using a SLIC-EPID.
    Appl Radiat Isot, 66(12): 1930-8. [Abstract] [Full-text]
  46. Measurement and comparison of skin dose for prostate and head-and-neck patients treated on various IMRT delivery systems.
    Appl Radiat Isot, 66(12): 1844-9. [Abstract] [Full-text]
  47. The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression.
    BMC Cancer, 8: 273. [Abstract] [Full-text]
  48. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.
    Adv Anat Pathol, 15(6): 319-31. [Abstract] [Full-text]
  49. Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR.
    BMC Cancer, 8: 284. [Abstract] [Full-text]
  50. The effect of hospital and surgeon volume on racial differences in recurrence-free survival after radical prostatectomy.
    Med Care, 46(11): 1170-6. [Abstract] [Full-text]
  51. Do prostatic transition zone tumors have a distinct morphology?
    Am J Surg Pathol, 32(11): 1709-14. [Abstract] [Full-text]
  52. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review.
    Int J Radiat Oncol Biol Phys, 72(4): 972-9. [Abstract] [Full-text]
  53. Calcifications are potential surrogates for prostate localization in image-guided radiotherapy.
    Int J Radiat Oncol Biol Phys, 72(4): 963-6. [Abstract] [Full-text]
  54. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 72(4): 980-8. [Abstract] [Full-text]
  55. Quality of life in men treated with carbon ion therapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 72(4): 1010-5. [Abstract] [Full-text]
  56. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy.
    Int J Radiat Oncol Biol Phys, 72(4): 996-1001. [Abstract] [Full-text]
  57. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer.
    Int J Radiat Oncol Biol Phys, 72(4): 1002-9. [Abstract] [Full-text]
  58. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria.
    Int J Radiat Oncol Biol Phys, 72(4): 989-95. [Abstract] [Full-text]
  59. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
    Oncology, 75(3): 230-6. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

The Prostate Cancer Protection Plan : The Foods, Supplements, and Drugs that Can Combat Prostate Cancer

The Prostate Cancer Protection Plan : The Foods, Supplements, and Drugs that Can Combat Prostate Cancer